Evidence map›Paper›PMID 38667313›Full record

ArticleCells2024

Further Characterization of the Antiviral Transmembrane Protein MARCH8.

Takuya Tada, Yanzhao Zhang, Dechuan Kong, Michiko Tanaka, Weitong Yao, Masanori Kameoka, Takamasa Ueno, Hideaki Fujita, Kenzo Tokunaga

Open access · goldAbstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Takuya TadaDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.ORCID 0000-0003-0779-9954
Yanzhao ZhangDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.ORCID 0000-0002-1937-4438
Dechuan KongDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.ORCID 0000-0003-3779-6666
Michiko TanakaDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Weitong YaoDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.ORCID 0000-0001-5441-9120
Masanori KameokaDepartment of Public Health, Kobe University Graduate School of Health Sciences, Kobe 650-0017, Japan.ORCID 0000-0001-5525-9915
Takamasa UenoJoint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-8555, Japan.ORCID 0000-0003-4852-4236
Hideaki FujitaFaculty of Pharmaceutical Sciences, Nagasaki International University, Sasebo 859-3298, Japan.ORCID 0000-0002-4105-4430
Kenzo TokunagaDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.ORCID 0000-0002-2625-5322
National Institute of Infectious Diseases · JPKobe University · JPKumamoto University · JPNagasaki International University · JP

Funding

Japan Society for the Promotion of Science 21K07060Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Scientific Research 21K06556
6 · The paper itself

Abstract

The cellular transmembrane protein MARCH8 impedes the incorporation of various viral envelope glycoproteins, such as the HIV-1 envelope glycoprotein (Env) and vesicular stomatitis virus G-glycoprotein (VSV-G), into virions by downregulating them from the surface of virus-producing cells. This downregulation significantly reduces the efficiency of virus infection. In this study, we aimed to further characterize this host protein by investigating its species specificity and the domains responsible for its antiviral activity, as well as its ability to inhibit cell-to-cell HIV-1 infection. We found that the antiviral function of MARCH8 is well conserved in the rhesus macaque, mouse, and bovine versions. The RING-CH domains of these versions are functionally important for inhibiting HIV-1 Env and VSV-G-pseudovirus infection, whereas tyrosine motifs are crucial for the former only, consistent with findings in human MARCH8. Through analysis of chimeric proteins between MARCH8 and non-antiviral MARCH3, we determined that both the N-terminal and C-terminal cytoplasmic tails, as well as presumably the N-terminal transmembrane domain, of MARCH8 are critical for its antiviral activity. Notably, we found that MARCH8 is unable to block cell-to-cell HIV-1 infection, likely due to its insufficient downregulation of Env. These findings offer further insights into understanding the biology of this antiviral transmembrane protein.

Indexed as

HIV-1Membrane ProteinsAnimalsAntiviral AgentsCattleenv Gene Products, Human Immunodeficiency VirusHEK293 CellsHIV InfectionsHumansMacaca mulattaMiceProtein DomainsUbiquitin-Protein LigasesAntiviral Agentsenv Gene Products, Human Immunodeficiency VirusMARCHF8 protein, humanMembrane ProteinsUbiquitin-Protein Ligasesantiviral activitycell-to-cell infectionHIVMARCH8species specificityVSV-G

Identifiers

PMID38667313
PMCPMC11049619
OpenAlexW4394932340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.